AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8302446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated with O2 = 4 1/min‐1 and N2O = 6 1/min‐1
Number of subjects: 24
Study 8302446 — intervention group
Group type: COMPARATOR
Intervention: Ventilated with O2 = 350 ml/min‐1 and N2O = 250 ml/min‐1, reducing N2O flow to keep FIO2 = 0.4
Number of subjects: 24
Study 3574803 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 152
Study 3574803 — intervention group
Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 152
Study 3574803 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin plus gentamicin
Number of subjects: 152
Study 30120069 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted NmCV-5
Number of subjects: 60
Study 30120069 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted NmCV-5
Number of subjects: 60
Study 30120069 — intervention group
Group type: COMPARATOR
Intervention: Control (Menactra)
Number of subjects: 60
Study 26980389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal douches based on high concentration (9 mg) and high-molecular-weight sodium hyaluronate (active treatment group)
Number of subjects: 94
Study 26980389 — intervention group
Group type: COMPARATOR
Intervention: Nasal saline solution irrigation (control group)
Number of subjects: 94
Study 25873781 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Preference Pacing ON
Number of subjects: 50
Study 25873781 — intervention group
Group type: COMPARATOR
Intervention: Atrial Preference Pacing OFF
Number of subjects: 50
Study 22327499 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (0, 6 month schedule)
Number of subjects: 0
Study 22327499 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (0, 12 month schedule)
Number of subjects: 0
Study 22327499 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV challenge dose
Number of subjects: 0
Study 20800922 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alfa 2b and ribavirin for 48 weeks
Number of subjects: 159
Study 20800922 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA class I alleles
Number of subjects: 159
Study 18278501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 63
Study 18278501 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 63
Study 15917152 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (60mg per day for 12 weeks)
Number of subjects: 57
Study 15917152 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract with PUFA supplement (two capsules per day for 24 weeks)
Number of subjects: 57
Study 15917152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two capsules per day for 12 weeks)
Number of subjects: 57
Study 12650788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy (OBMT) with omeprazole, bismuth biskalcitrate 140 mg, metronidazole 125 mg, and tetracycline 125 mg for 10 days.
Number of subjects: 275
Study 12650788 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (OAC) with omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg for 10 days.
Number of subjects: 275
Study 10817585 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping and linkage analysis of alpha2-macroglobulin genetic markers (A2MI and A2M2) in Japanese AD patients
Number of subjects: 426
Study 10817585 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping and linkage analysis of alpha2-macroglobulin genetic markers (A2MI and A2M2) in Caucasian AD patients
Number of subjects: 426
Study 10817585 — intervention group
Group type: COMPARATOR
Intervention: Comparison of genotype and allele frequencies in cognitively normal controls
Number of subjects: 426
Study 10817585 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 426
Study 8646868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate ointment, 0.005%
Number of subjects: 113
Study 8646868 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate ointment, 0.1%
Number of subjects: 113
Study 1996888 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (58 infants)
Number of subjects: 102
Study 1996888 — intervention group
Group type: COMPARATOR
Intervention: Clinically diagnosed group (44 children)
Number of subjects: 102
Study 6373152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg oxaprozin once daily
Number of subjects: 24
Study 6373152 — intervention group
Group type: COMPARATOR
Intervention: 250 mg naproxen 3-times daily
Number of subjects: 24
Study 30852374 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX plus Abstinence Incentives
Number of subjects: 84
Study 30852374 — intervention group
Group type: EXPERIMENTAL
Intervention: XR‐NTX
Number of subjects: 84
Study 30852374 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence Incentives
Number of subjects: 84
Study 30852374 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 84
Study 30558933 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vacuum
Number of subjects: 12
Study 30558933 — intervention group
Group type: COMPARATOR
Intervention: Inactive vacuum
Number of subjects: 12
Study 27248336 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated-TLIF
Number of subjects: 40
Study 27248336 — intervention group
Group type: COMPARATOR
Intervention: Conventional-TLIF
Number of subjects: 40
Study 27248336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25027339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoselis
Number of subjects: 276
Study 25027339 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 276
Study 22251483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-based immunotherapy
Number of subjects: 0
Study 22251483 — intervention group
Group type: COMPARATOR
Intervention: Cytokine alone
Number of subjects: 0
Study 22251483 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied immunomodulatory treatment
Number of subjects: 0
Study 20705755 — intervention group
Group type: EXPERIMENTAL
Intervention: As(2)O(3) consolidation
Number of subjects: 481
Study 20705755 — intervention group
Group type: COMPARATOR
Intervention: Standard induction and consolidation therapy
Number of subjects: 481
Study 17620446 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 30 min after dosing (EX30)
Number of subjects: 23
Study 17620446 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 120 min after dosing (EX120)
Number of subjects: 23
Study 17620446 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min exercise starting 240 min after dosing (EX240)
Number of subjects: 23
Study 17620446 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NOEX group)
Number of subjects: 23
Study 16332666 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg) plus vitamin B‐12 (500 microg)
Number of subjects: 185
Study 16332666 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B‐6 (25 mg)
Number of subjects: 185
Study 16332666 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin (25 mg)
Number of subjects: 185
Study 16332666 — intervention group
Group type: COMPARATOR
Intervention: Control (no folic acid plus vitamin B‐12)
Number of subjects: 185
Study 11976239 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive H pylori test
Number of subjects: 708
Study 11976239 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy plus H pylori testing
Number of subjects: 708
Study 9477931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 30
Study 9477931 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (control)
Number of subjects: 30
Study 8583673 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam syrup
Number of subjects: 77
Study 8583673 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam suppository
Number of subjects: 77
Study 2476520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclatonium (300 mg)
Number of subjects: 6
Study 2476520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 20005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibencozide
Number of subjects: 0
Study 20005 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 30694377 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI through intravenous gadolinium administration (IV-Gd)
Number of subjects: 56
Study 30694377 — intervention group
Group type: EXPERIMENTAL
Intervention: oVEMP
Number of subjects: 56
Study 30694377 — intervention group
Group type: EXPERIMENTAL
Intervention: cVEMP
Number of subjects: 56
Study 30694377 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 56
Study 30694377 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric tests
Number of subjects: 56
Study 28362843 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation to the right DLPFC
Number of subjects: 0
Study 28362843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study 26124497 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 0
Study 26124497 — intervention group
Group type: EXPERIMENTAL
Intervention: Capizzi methotrexate (C-MTX)
Number of subjects: 0
Study 26124497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy for MRD >0.1%
Number of subjects: 0
Study 26124497 — intervention group
Group type: EXPERIMENTAL
Intervention: End-induction MRD <0.01%
Number of subjects: 0
Study 26124497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from MRD positive to negative by end consolidation
Number of subjects: 0
Study 22888759 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised kinesiotherapy aimed at improvement of muscle activity and headache symptoms releasing.
Number of subjects: 40
Study 22888759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study 21209585 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (coping strategies, mental rehearsal, relaxation)
Number of subjects: 16
Study 21209585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 17914032 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (45 mg)
Number of subjects: 31
Study 17914032 — intervention group
Group type: COMPARATOR
Intervention: metformin (2,000 mg)
Number of subjects: 31
Study 17243597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch three-step (TE3) dentin adhesive system with correct application
Number of subjects: 70
Study 17243597 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive drying of primer
Number of subjects: 70
Study 17243597 — intervention group
Group type: EXPERIMENTAL
Intervention: Short application of primer by immediate drying
Number of subjects: 70
Study 17243597 — intervention group
Group type: EXPERIMENTAL
Intervention: No drying of primer
Number of subjects: 70
Study 17243597 — intervention group
Group type: EXPERIMENTAL
Intervention: No primer application
Number of subjects: 70
Study 15280105 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 3 g daily orally for 20 days
Number of subjects: 108
Study 15280105 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 108
Study 11762418 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (e.g., Rituxan, Mylotarg, Campath)
Number of subjects: 0
Study 11762418 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies as monotherapy or in combination with conventional chemotherapies
Number of subjects: 0
Study 11762418 — intervention group
Group type: EXPERIMENTAL
Intervention: Engineered antibodies
Number of subjects: 0
Study 11762418 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody engineering
Number of subjects: 0
Study 9274891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152
Study 9274891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 7829762 — intervention group
Group type: EXPERIMENTAL
Intervention: brofaromine 150 mg daily (n = 111)
Number of subjects: 220
Study 7829762 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 109)
Number of subjects: 220
Study 7829762 — intervention group
Group type: EXPERIMENTAL
Intervention: brofaromine 150 mg daily
Number of subjects: 220
Study 3284501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride (n = 23)
Number of subjects: 53
Study 3284501 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (n = 30)
Number of subjects: 53
Study 30149282 — intervention group
Group type: EXPERIMENTAL
Intervention: Untouched selfie
Number of subjects: 110
Study 30149282 — intervention group
Group type: EXPERIMENTAL
Intervention: Retouched selfie
Number of subjects: 110
Study 30149282 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 27998964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg daily plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Number of subjects: 0
Study 27998964 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Number of subjects: 0
Study 27998964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus gemcitabine
Number of subjects: 0
Study 27998964 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 0
Study 26165360 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staples (Leukosan® SkinStapler PTW‐35, BSN, Germany)
Number of subjects: 231
Study 26165360 — intervention group
Group type: COMPARATOR
Intervention: Continuous 3.0 intradermal non-absorbable polypropylene suture (Prolene™ 0, Ethicon Inc. Somerville, New Jersey, USA)
Number of subjects: 231
Study 23715754 — intervention group
Group type: EXPERIMENTAL
Intervention: GFT505 (80 mg/day)
Number of subjects: 22
Study 21393146 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine laboratory monitoring
Number of subjects: 0
Study 21393146 — intervention group
Group type: COMPARATOR
Intervention: Clinically driven monitoring
Number of subjects: 0
Study 18435857 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive booklet on respiratory tract infections
Number of subjects: 0
Study 18435857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16574037 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐ERMS once daily in AM or PM for a 4‐week treatment period
Number of subjects: 1428
Study 14599939 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy after pre-ligation of the hepatic inflow and outflow blood vessels of the lesioned liver lobe (Group B)
Number of subjects: 68
Study 14599939 — intervention group
Group type: COMPARATOR
Intervention: Pringle's maneuver (Group A)
Number of subjects: 68
Study 11007154 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic model of condom use outcomes
Number of subjects: 4638
Study 11007154 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-concept and pleasure
Number of subjects: 4638
Study 11007154 — intervention group
Group type: EXPERIMENTAL
Intervention: Protection and interaction
Number of subjects: 4638
Study 9402690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Number of subjects: 18
Study 9402690 — intervention group
Group type: COMPARATOR
Intervention: CsA with MMF (1.0 g bid)
Number of subjects: 18
Study 9402690 — intervention group
Group type: COMPARATOR
Intervention: CsA with MMF (1.5 g bid)
Number of subjects: 18
Study 9402690 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA and tacrolimus
Number of subjects: 18
Study 8210830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Poisson-gamma regression method
Number of subjects: 0
Study 8210830 — intervention group
Group type: COMPARATOR
Intervention: Quasi-likelihood method
Number of subjects: 0
Study 8210830 — intervention group
Group type: EXPERIMENTAL
Intervention: Thall method
Number of subjects: 0
Study 8210830 — intervention group
Group type: COMPARATOR
Intervention: Zeger and Liang method
Number of subjects: 0
Study 3535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 298
Study 3535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 298
Study 3535134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 298
Study 31135579 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 0
Study 31135579 — intervention group
Group type: COMPARATOR
Intervention: Salpingo-oophorectomy
Number of subjects: 0
Study 31135579 — intervention group
Group type: COMPARATOR
Intervention: Concomitant salpingectomy
Number of subjects: 0
Study 29638148 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg IV infusion twice daily for up to 14 days
Number of subjects: 274
Study 29638148 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 50 mg/h continuous IV infusion following an initial bolus of 300 mg for up to 14 days
Number of subjects: 274
Study 30182671 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 75
Study 30182671 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 75
Study 30182671 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Levocetirizine and Montelukast
Number of subjects: 75
Study 30182671 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study 25560825 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming legacy motives
Number of subjects: 0
Study 25560825 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy motivation
Number of subjects: 0
Study 23535873 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4 g · d(‐1) for 4 weeks)
Number of subjects: 20
Study 23535873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 20
Study 23535873 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine with sodium bicarbonate
Number of subjects: 20
Study 20495586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 70
Study 20495586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections with 0.5% lidocaine (4 mL) mixed with 1 mL of non-particulate betamethasone
Number of subjects: 70
Study 17983686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 108
Study 17983686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 15985032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.77% gel applied twice daily
Number of subjects: 100
Study 15985032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.77% gel applied once daily
Number of subjects: 100
Study 15985032 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 100
Study 12325402 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (two 40‐min sessions per week for 5 weeks)
Number of subjects: 20
Study 12325402 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (range of motion exercise routine targeting arms, neck, shoulders, and back, 2 times per week for 5 weeks)
Number of subjects: 20
Study 10526701 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991
Study 10526701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study 7795096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 82
Study 7795096 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMZ (640 mg/3,200 mg)
Number of subjects: 82
Study 2343070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg haloperidol
Number of subjects: 6
Study 2343070 — intervention group
Group type: EXPERIMENTAL
Intervention: reduced haloperidol
Number of subjects: 6
Study 7000476 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg chenodeoxycholic acid (CDC)/day
Number of subjects: 35
Study 7000476 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg chenodeoxycholic acid (CDC)/day
Number of subjects: 35
Study 7000476 — intervention group
Group type: COMPARATOR
Intervention: 375 mg CDC/day (after 6 months for placebo patients)
Number of subjects: 35
Study 31568489 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN + IRS
Number of subjects: 34548
Study 31568489 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN alone
Number of subjects: 34548
Study 31568489 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS alone
Number of subjects: 34548
Study 31568489 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34548
Study 27646824 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless, Accelerometry‐Triggered Functional Electrical Stimulation (WAFES)
Number of subjects: 20
Study 27646824 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 20
Study 26180108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose target of 100‐140 mg/dL (n = 151)
Number of subjects: 302
Study 26180108 — intervention group
Group type: COMPARATOR
Intervention: Conservative glucose target of 141‐180 mg/dL (n = 151)
Number of subjects: 302
Study 26180108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen in patients without diabetes
Number of subjects: 302
Study 26180108 — intervention group
Group type: COMPARATOR
Intervention: Conservative regimen in patients without diabetes
Number of subjects: 302
Study 26180108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimen in patients with diabetes
Number of subjects: 302
Study 26180108 — intervention group
Group type: COMPARATOR
Intervention: Conservative regimen in patients with diabetes
Number of subjects: 302
Study 24375220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Targin (oxycodone-hydrochloride and naloxone hydrochloride-dihydrate)
Number of subjects: 51
Study 24375220 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled IV morphine
Number of subjects: 51
Study 22934858 — intervention group
Group type: EXPERIMENTAL
Intervention: Long thoracic nerve (LTN) block
Number of subjects: 0